BUZZ-Bright Minds Biosciences falls after $100 mln equity offering launched
I'm PortAI, I can summarize articles.
Bright Minds Biosciences' shares fell 11.8% to $82.25 following a $100 million equity offering announcement. The Canadian biotech firm had previously seen a surge of up to 55% after positive Phase 2 trial results for its epilepsy drug, BMB-101. TD Cowen maintains a 'buy' rating, noting the trial data exceeded expectations. The company plans to use the proceeds for future clinical trials. Analysts remain optimistic, with a median price target of $142.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments